Improving understanding of type 2 diabetes remission: research recommendations from Diabetes UK's 2019 remission workshop by Andrews, Rob
Diabetes UK Position Statements
Improving understanding of type 2 diabetes remission:
research recommendations from Diabetes UK’s 2019
remission workshop
M. Hopkins1 , R. Andrews3 , V. Salem2 , R. Taylor4 , C. W. le Roux5 ,
E. Robertson1 and E. Burns1
1Diabetes UK, 2Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, 3University of Exeter Medical
School, Royal Devon and Exeter Hospital, Exeter, UK, 4Newcastle Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Newcastle, UK
and 5Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland
Accepted 26 June 2020
Abstract
Aim To describe the process and outputs of a workshop convened to identify key priorities for future research in the
area of remission of type 2 diabetes, and provide recommendations to researchers and research funders on how best to
address them. With the ultimate aim of enabling the remission of type 2 diabetes to become a possibility for more people.
Methods A 1-day research workshop was conducted, bringing together 31 researchers, people living with diabetes,
healthcare professionals and members of staff from Diabetes UK to identify and prioritize recommendations for future
research into remission of type 2 diabetes.
Results Workshop attendees identified 10 key themes for further research. Four of these themes were prioritized for
further focus: (i) understanding how to personalize lifestyle approaches based on biology, patient choice and subtypes;
(ii) understanding the biology of remission; (iii) understanding the most effective approaches to implementation of
lifestyle interventions; and (iv) understanding the best approaches to combining therapies (gut hormones, other drugs,
lifestyle approaches and bariatric surgery).
Conclusions This paper outlines recommendations to address the current gaps in knowledge related to remission of
type 2 diabetes.
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Introduction
Can type 2 diabetes be cured or reversed, what is the best
way to achieve this and is there a point beyond which the
condition can’t be reversed?
This was the number one priority raised by people with type
2 diabetes and healthcare professionals, as part of the type 2
diabetes James Lind Alliance Priority Setting Partnership –
involving insight from over 4000 people [1].
It has been known for a number of decades that remission
of type 2 diabetes is possible [2], with bariatric surgery
resulting in remission of hyperglycaemia in 30–60% of cases
[3]. However, access to bariatric surgery is limited, meaning
that only a relatively small number of people with type 2
diabetes currently access this treatment. Recent evidence has
also emerged showing that lifestyle interventions can induce
and maintain type 2 diabetes remission. The Diabetes
Remission Clinical Trial (DiRECT) demonstrated that 10–
15% weight loss after a low-calorie weight management
programme delivered through primary care can lead to
remission for at least 2 years in 36% of people [4] but low
calorie weight management programmes are not as yet
routinely available within the UK National Health Service
(NHS).
As therapies become more commonly available, to ensure
that as many people as possible can benefit from these
approaches there is a need to both clearly define remission
and for research to further our understanding of remission
and what it means for people with type 2 diabetes.
The Association of British Clinical Diabetologists (ABCD)
and the Primary Care Diabetes Society (PCDS) have pub-
lished a consensus statement defining remission based on
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three criteria: (i) weight loss, (ii) HbA1c < 48 mmol/mol
(6.5%) on two occasions with at least a 6-month interval
between them, and (iii) cessation of all glucose-lowering
therapies [5]. Work is also ongoing between the American
Diabetes Association (ADA), European Association for the
Study of Diabetes (EASD) and Diabetes UK to agree an
international consensus definition for type 2 diabetes remis-
sion.
To further enhance our understanding of remission of type
2 diabetes, Diabetes UK convened a workshop with the aim
of identifying priorities for future research.
Methodology
In July 2019, Diabetes UK brought together diabetes clinical
studies group (CSG) members and experts from a variety of
backgrounds, including people living with type 2 diabetes,
for a 1-day workshop to identify the key gaps in evidence and
priority research questions in the area of type 2 diabetes
remission. In total, there were 31 attendees, including four
people living with diabetes, 20 researchers and healthcare
professionals, and five members of staff from Diabetes UK
who facilitated the workshop. Attendees are listed in
Appendix S1.
The workshop format began with three presentations from
experts in the field. These presentations provided an over-
view of current evidence related to remission of type 2
diabetes in relation to lifestyle interventions (Professor Roy
Taylor), bariatric surgery (Professor Carel le Roux) and gut
hormone research (Dr Victoria Salem).
After each presentation, attendees were organized into the
same group of six or seven, with representation from
different specialities and a person with or in remission of
type 2 diabetes, and were asked to discuss and answer three
questions: (i) where are the current areas of strength in
existing research evidence; (ii) how can this evidence be built
on; and (iii) where is further evidence needed?
Each group was asked to identify one or two priorities for
further research. In total, around 40 research priorities were
identified. The Diabetes UK facilitation team then clustered
these priorities into 10 themes:
 How can lifestyle interventions be personalized, based on
biology, individual choice and variation?
 Can we better understand the biology of remission (e.g.
why responses differ, how these differences could be
measured)?
 How can lifestyle interventions be implemented most
effectively (including approaches to weight loss and
maintenance, scalability, and models of delivery)?
 Who is most likely to benefit from bariatric surgery (e.g.
could biomarkers be used to predict response) and when
should it be offered?
 What is the psychological impact of bariatric surgery,
remission and no longer being in remission (including use
of language)?
 Is bariatric surgery an effective way to reach remission in
young people with type 2 diabetes?
 What are the factors affecting access to bariatric surgery
(considering both the barriers and enablers, as well as the
impact of stigma)?
 How and where do gut hormones work (including their
safety profiles and effects on other organs)?
 How could gut hormone therapy be personalized (e.g.
could genetics be used to predict response)?
 What are the best approaches to combining therapies (gut
hormones, other drugs, lifestyle approaches and bariatric
surgery)?
In order to focus discussions further, each workshop
attendee was asked to vote for their top three themes, the
results of this vote can be seen in Table S1.
Following this voting exercise, the top five themes were
identified and attendees were individually asked to choose
the theme they wished to focus on for the remainder of the
workshop. One theme—understanding who will benefit most
from bariatric surgery—was not prioritized because no
workshop attendees chose it as an area for further discussion.
The four themes which were prioritized for in-depth discus-
sion were:
1. Understanding how to personalize lifestyle approaches
based on biology, patient choice and subtypes.
2. Understanding the biology of remission.
3. Understanding the most effective approaches to imple-
mentation of lifestyle interventions.
4. Understanding the best approaches to combining therapies
(gut hormones, other drugs, lifestyle approaches and
bariatric surgery).
What’s new?
• It is known that type 2 diabetes can be put into
remission; however, standard clinical treatment of type
2 diabetes does not currently aim to put the condition
into remission.
• This is the first time that researchers and healthcare
professionals from a wide range of specialist areas have
come together to identify research priorities to increase
understanding of remission of type 2 diabetes.
• The paper sets out key recommendations for further
research that is needed in order to make remission an
achievable aim for more people with type 2 diabetes.
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Each group was asked to discuss three questions: (i) what
are the research questions; (ii) what approaches could be
taken to answer these questions; and (iii) what are the
barriers to this research and how could they be overcome?
Each group was asked to feedback on their discussions,
and other attendees had the opportunity to input thoughts
and ideas. All discussions were captured to inform this paper.
This paper provides a summary of these discussions and
the key research priorities that were identified in order to
advance our understanding of remission of type 2 diabetes.
We note that some of the priorities outlined move beyond the
scope of the themes; however, they do represent the output of
these discussions.
Research priorities and recommendations
Theme 1: Understanding the biology of remission
b-Cell function
Findings from DiRECT indicate that significant weight loss
can result in a reduction in the levels of fat within the
pancreas and liver [6], and in turn, improve b-cell function
[7]. However, a small number of DiRECT participants who
lost significant weight did not go into remission; reduced
levels of fat within their pancreas and liver did not result in
improved b-cell function. Further research is needed to
understand the reasons behind these differences, and the
potential need for stratification in future remission pro-
grammes.
Mechanisms behind bariatric surgery
There are a number of different bariatric surgery procedures
and current evidence suggests that these can lead to the
remission of type 2 diabetes in 30–60% of people [3].
However, evidence also suggests that 35–50% of people who
initially go into remission will experience recurrence of the
condition [3]. A recent population study of type 2 diabetes
remission rates following Roux-en-Y gastric bypass (RYGB)
surgery found that 73% of people in remission at 12 months
were still in remission at 5 years [8]. The study also identified
potential predictive factors for not achieving remission, such
as age > 50 years, diabetes duration of > 5 years, use of
glucose-lowering medication other than metformin, and a
baseline HbA1c > 53 mmol/mol (7.0%).
Bariatric surgery was noted to enhance levels of postpran-
dial satiety gut hormone responses, leading to reduced
appetite and food intake [9]. Changes to gut hormone levels
have been suggested as one of the mechanisms responsible for
improvements in glycaemic control after surgery, particularly
before significant weight loss has occurred [10], and the gut
hormone incretin glucagon-like peptide 1 (GLP-1) has
already been developed into treatments for type 2 diabetes
and obesity. Dual treatment with GLP-1 and glucagon has
been shown to significantly reduce food intake compared
with monotherapy [11], and improve bodyweight, fasting
glucose and glucose tolerance [12]. A separate small study
into the use of a triple agonist (GLP-1, oxyntomodulin and
peptide YY) replicated the gut hormone responses seen post-
RYGB and led to reduced food intake, albeit not to the same
magnitude as surgery itself, and normalized glycaemic
control [13].
However, gut hormones may not be the only factor behind
normalization of glycaemic control after bariatric surgery
[14], given that reduced calorie intake—whether through
diet alone or bariatric surgery—can bring about normaliza-
tion of glycaemic control after 7 days, with the underlying
mechanisms shown to be the same [15,16]. Decreased food
intake brings about marked normalization of hepatic fat
content and hepatic insulin sensitivity, and these factors are
capable of decreasing the output of glucose from the liver
and decreasing fasting plasma glucose [15–17].
As such, further research is needed to explore how
combination hormone therapies could be used to aid weight
loss, promote weight loss maintenance, augment glycaemic
control and improve health outcomes in the future.
Predicting responses
The potential use of biomarkers to provide more personal-
ized diabetes treatment is of increasing interest [18]. A
greater understanding of the biomarkers that could be used
to predict responses to remission interventions would also be
beneficial, to support people with type 2 diabetes and
healthcare professionals to make informed choices about
the most appropriate treatment plans and clinical pathways.
Research priorities
The group recommended that further research is needed to
build a greater understanding of:
 the biology of b-cell recovery, to stratify and target future
remission interventions;
 the role of gut hormone therapy in remission, particularly
building on initial small-scale studies; and
 novel biomarkers which could be used to predict response
to remission interventions in the future.
Theme 2: Understanding how to personalize lifestyle
approaches based on biology, individual choice and variation
Evidencing different lifestyle interventions
In order to make remission a reality for as many people
with type 2 diabetes as possible, we are likely to need a
variety of lifestyle interventions, to meet the physiological,
psychological and cultural needs of each individual. Fur-
ther research to develop a rigorous evidence-based suite of
options would improve individual choice and personaliza-
tion.
Currently, the strongest evidence of remission exists for the
use of a low-calorie weight management programme and
bariatric surgery [3,4].
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Some industry-funded studies have also suggested that
low-carbohydrate diets may result in remission for some
people (17.6% of participants were in remission 2 years post
intervention initiation) [19], and there are many self-reported
cases of remission using this approach. More rigorous
research is required to build evidence in this area, in order
to influence clinical practice, and a number of research
questions around the effects of low-carbohydrate diets were
identified:
 What constitutes a low-carbohydrate diet?
 Can a low-carbohydrate diet restore normal glucose and
insulin metabolism and achieve remission of type 2
diabetes in the long-term?
 What is the long-term impact of a low-carbohydrate diet
on other aspects of health, particularly the effects of
relatively increasing or decreasing other macronutrients;
for example, lipids on cardiovascular outcomes or protein
on kidney function?
 Could a low-carbohydrate diet be used to support people
to maintain weight loss after other dietary approaches?
 Do low-carbohydrate diets provide additional health
benefits for people with type 2 diabetes, or people in
remission, beyond weight loss?
Effective approaches for people of different ethnicities
There is a current gap in evidence regarding the effectiveness
of low-calorie weight management programmes in people of
different ethnicities. DiRECT participants were largely rep-
resentative of the local populations in the trial areas, but they
were predominantly white [4]. There is a need to identify
effective lifestyle approaches to remission for people from
black, Asian and minority ethnic (BAME) populations, and
this will involve a more in-depth understanding of both
physiological and cultural factors which may affect effec-
tiveness. For example, preliminary research has suggested
that the biology underlying the development of type 2
diabetes may differ in black African men, suggesting that
more tailored prevention or remission options may be
required [20]. However, initial findings from a recent
feasibility study in a small group of people who were
predominantly black suggest that a low-calorie diet could be
effective in restoring normal glucose and insulin metabolism
[21].
Research priorities
The group recommended that further research is needed to
build a greater understanding of:
 the role of low-carbohydrate diets in remission, particu-
larly through robust clinical trials; and
 the effectiveness of different lifestyle interventions in
different BAME communities, requiring more diverse
representation in future studies.
Theme 3: Understanding the most effective approaches to
implementing interventions
Meeting local and national needs
To ensure that more people can achieve remission of type 2,
local and national health services will need to begin to offer
effective, remission services.
In the UK, the NHS has responded to the latest evidence
around low-calorie weight management programmes, with
rapid moves to begin implementation of such programmes
within the NHS. The NHS in England has begun planning a
pilot programme for ~ 5000 people with type 2 diabetes
[22], and commissioners within a number of local health
economies in England have begun to commission and
procure remission programmes. The NHS in Scotland has
also begun to roll out remission programmes in some parts of
the country [23].
There are a number of challenges in translating research
into clinical practice. Within the UK, there is significant
variation in how the NHS is organized at a national, regional
and local level, as well as competing demands for funding
and workforce capacity. Against this backdrop, there will be
a desire to find ways of adapting evidence-based programmes
to meet local circumstances. For example, changes could
include the use of group-based consultations, digital plat-
forms or remote interventions.
As such, evaluations of how these changes could impact
the efficacy and cost-effectiveness of such programmes is
needed, to inform future commissioning decisions. Some
studies exploring different options are now underway [24].
Research exploring the effectiveness of the implementation
of these interventions will provide useful evidence both to the
UK and for other health systems internationally as they
consider their approaches to treat type 2 diabetes.
Maintaining weight loss
Evidence suggests that maintaining weight loss after a
lifestyle intervention is key to long-term remission, with
significant weight gain resulting in the re-emergence of
type 2 diabetes [3]. A large number of studies have
investigated the effectiveness of behaviour change inter-
ventions, but there is limited research into the sustainabil-
ity of behaviour change after the intervention phase ends
[25]. Therefore, further research is needed to identify
evidence-based approaches to supporting people to main-
tain weight loss.
DiRECT demonstrated that intensive support in partici-
pants who regained some weight, through an optional ‘rescue
protocol’ involving a further short period of low-calorie meal
replacements, was effective in supporting some people to stay
in remission at 24 months [4]. Questions remain regarding
the practicality of offering repeat ‘rescue’ packages within
normal clinical practice. Research into the efficacy and cost-
effectiveness of the long-term use of ‘rescue’ packages,
compared with one-off upfront interventions, to support
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weight maintenance would help to support the effective
implementation of ongoing support to maintain weight loss.
Further research to identify effective approaches for
supporting people to maintain weight loss, and therefore
potentially remain in remission, in the long term is now
needed. This includes research to build our understanding of
the role of physical activity, both in weight loss and long-
term weight maintenance. Greater collaboration between
researchers working in the fields of diet, physical activity and
psychology could be beneficial to support this.
Acceptability and wider long-term impact
With the concept of remission being relatively novel, there is
now a need to better understand how its introduction into
the diabetes field has affected both research study designs and
care pathways, and this will require insight from people with
type 2 diabetes and healthcare professionals.
Further research into the psychological effects of remission
is also required, including research to establish the impact of
re-emerging type 2 diabetes, significant dietary changes
during weight loss, and the potential risks of developing
disordered eating.
The number of people who receive bariatric surgery in the
UK is lower than most other European countries [26].
Research is needed to identify the barriers preventing greater
uptake of bariatric surgery and ways to overcome them. This
would need to involve an exploration of the views of people
with type 2 diabetes, healthcare professionals and the wider
public, the political and commissioning challenges that limit
funding, and the clinical pathways for surgery.
Research priorities
The group recommended that further research is needed to
build a greater understanding of:
 the impact of different delivery models of lifestyle inter-
ventions on their efficacy in real-world settings;
 the health economic implications of remission interven-
tions;
 evidence-based approaches to maintaining weight loss,
including the role of physical activity and the efficacy and
cost-effectiveness of ‘rescue’ packages within lifestyle
interventions;
 the psychological impact of each aspect of remission,
including on those people who are not able to go into
remission;
 barriers to the greater uptake of bariatric surgery.
Theme 4: Understanding the best approaches to combining
therapies (gut hormones, other drugs, lifestyle approaches
and bariatric surgery)
Individually, hormone therapies, lifestyle interventions and
bariatric surgery have all been shown to support
improvements in blood glucose levels, with the possibility
of putting type 2 diabetes into remission for some.
As understanding of the underlying biology of remission
improves, there could be potential in exploring the efficacy of
combination therapies to enable a significant reduction in
blood glucose levels to put type 2 diabetes into remission and
maintain this in the long term. There are a range of
combinations which could be tested. For example, given
the importance of weight loss maintenance in sustaining
remission following lifestyle interventions, post-intervention
hormone therapies could potentially be used to support
weight maintenance.
Further research into the efficacy and cost-effectiveness of
different combination therapy approaches needs to be
established. For example, in the case of type 2 diabetes
remission, health funders may be motivated by both
improved health outcomes and the potential to reduce
spending on high-cost drugs. The cost implications of
introducing hormone therapies to maintain remission would
therefore need to be explored.
Further research is also needed to align potential combi-
nation therapy options with the variation within type 2
diabetes, through an increased understanding of how to
effectively stratify people living with the condition. In the
future, this could enable healthcare professionals to target
more aggressive combination therapies to people at greatest
risk of progression to complications.
Research priorities
The group recommended that further research is needed to
build a greater understanding of:
 the potential of combination interventions and therapies,
including their efficacy and cost-effectiveness; and
 how to effectively stratify type 2 diabetes and align
remission interventions with the individual.
Collaboration and involvement
Workshop discussions highlighted the significant interest
in understanding remission among the research commu-
nity, with many people already working within the field.
One of the messages repeated throughout the day by
different people was that greater collaboration among
researchers would benefit the field in making further
progress.
Large-scale trials involving high numbers of participants
are needed to answer some of the questions within this
paper.Although this presents significant challenges, includ-
ing funding, there is the opportunity andpotential to embed
relevant research in large-scale health programmes.
Greater collaboration between health systems and the
research community could lead to greater advances in our
understanding of remission, and ultimately lead to more
people in remission of type 2 diabetes.
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Conclusion
How to put type 2 diabetes into remission is the most
important research question for people living with the
condition [1]. The research community has made great
strides in making remission a possibility for some people
with type 2 diabetes, but as this paper sets out, many
more questions remain to be answered.
Diabetes UK has identified remission of type 2 diabetes as a
key strategic priority for the years ahead [27]. Addressing the
recommendations for future research set outwithin this paper,
in collaboration with researchers, funders, health services and
peoplewith diabetes,will enable us tomake remissionof type2
diabetes a reality for as many people as possible.
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